You are here
Daclizumab Phase 2 Trial Results Fail To Demonstrate Clinical Benefit in Ulcerative Colitis
FREMONT, Calif., May 16 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) today reported that its humanized antibody, daclizumab, did not meet the primary endpoint in a Phase II clinical trial in patients with moderate or severe ulcerative colitis. The primary efficacy endpoint in the study, the proportion of patients who achieved remission at week eight, did not meet statistical significance at either of the dose levels tested. Treatment with daclizumab antibody product was well tolerated.
Steven Benner, M.D., Senior Vice President and Chief Medical Officer, PDL, said, "We are disappointed that daclizumab did not demonstrate a clinical benefit in this setting. Based on these findings, we do not plan to further develop daclizumab as a treatment for ulcerative colitis.
"We remain firmly committed to the development of novel therapies in inflammatory bowel disease with the ongoing development of our Nuvion® antibody product for the potential treatment of patients with severe ulcerative colitis who failed to respond to treatment with intravenous steroids," Dr. Benner continued. "Based on recent encouraging Phase I results, as well as potential time to market, we continue to view Nuvion as our highest priority program.
"We are also committed to further development of daclizumab in additional indications, with top priority now in patients with chronic, persistent asthma," Dr. Benner added. "Our current plan is to follow the positive Phase II data in this setting reported earlier this year with a follow-on study. As the second priority for daclizumab, we also continue preparatory work for a PDL clinical trial in patients with multiple sclerosis. Our current plans are to initiate a follow-on study in each of asthma and multiple sclerosis by the first quarter of 2005."
Phase II Study Design
The randomized, double-blind, placebo-controlled Phase II clinical trial enrolled 159 patients at approximately 40 sites in North America and Europe. Patients were randomized to receive either daclizumab at 1 mg/kg at a four-week interval for a total of two doses, or 2 mg/kg every two weeks for a total of four doses, or placebo. The primary study objectives were safety and achievement of remission, defined by the Mayo score. Patients eligible for entry into the trial had evidence of active ulcerative colitis at baseline.
The FDA approved daclizumab for use in transplantation in December 1997, making it the first humanized antibody to gain marketing clearance in the United States. Daclizumab currently is marketed as Zenapax® by Roche for prevention of acute rejection in kidney transplantation. In September 2003, PDL and Roche announced that PDL had re-acquired from Roche the rights to market and manufacture daclizumab in indications other than transplantation, and an option to acquire rights in transplantation exercisable in 2006 and effective in 2007.
Source: Protein Design Labs, Inc.